Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDX184 in Treatment-Naïve Genotype 1 Chronic Hepatitis C
NCT00807001Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Primary completion
- Jul 2009
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
01
Overview
Phase 2, randomised, double-blind trial of IDX184 in hepatitis C (HCV) (5 arms), sponsored by Merck & Co. Primary endpoint: Number of Subjects With Any Adverse Event and the Severity of Those Adverse Events at 17 days. Started Dec 2008; status: completed.
02
Drugs
IDX184
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00807001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00807001.